228. Bronchiolitis obliterans Clinical trials / Disease details

Clinical trials : 97 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 33 - Drug target pathways : 156

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04239989 (ClinicalTrials.gov)	April 8, 2021	30/12/2019	Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant	A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplant (HCT)	Bronchiolitis Obliterans	Drug: Itacitinib;Drug: Itacitinib Adipate	M.D. Anderson Cancer Center	NULL	Recruiting	18 Years	75 Years	All	15	Phase 1	United States
2	NCT04640025 (ClinicalTrials.gov)	March 10, 2021	18/11/2020	A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib	A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)	Myelofibrosis;Postlung Transplant (Bronchiolitis Obliterans);Chronic Graft Versus Host Disease	Drug: itacitinib	Incyte Corporation	NULL	Recruiting	18 Years	N/A	All	100	Phase 2	United States;Austria;Belgium;Canada;Germany;Greece;Israel;Italy;Spain
3	NCT03978637 (ClinicalTrials.gov)	February 4, 2020	5/6/2019	Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation	An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation	Bronchiolitis Obliterans Syndrome	Drug: Itacitinib	Incyte Corporation	NULL	Active, not recruiting	18 Years	N/A	All	23	Phase 1/Phase 2	United States;Belgium;Canada